10.27.23 -- Access Solutions Tailored To Your Development And Manufacturing Needs

With available capacity for the development and drug substance manufacturing of biologics, as well as drug product and finished goods capabilities, FDB is poised to support your molecule's journey with end-to-end CDMO services.

Singota Solutions, a CDMO performing supply chain management, laboratory, and manufacturing services in support of drug development, shares current and projected capacity over the next 6-12 months for the various service line offerings.

Drug product services are a key cornerstone in Lonza's biologics offer. Learn more as Reto Renggli, drug product services at Lonza, provides a comprehensive overview on how Lonza can support your drug product development and manufacturing needs.

Ajinomoto Bio-Pharma Services is a leading biopharmaceutical CDMO. Review Aji Bio-Pharma’s array of clinical through commercial manufacturing capabilities as well as the new high-speed multipurpose fill/finish line in its state-of-the-art facility.

Simtra BioPharma Solutions (Simtra) is a premier CMO with a singular focus on sterile injectable drug product form/fill/finish services. Simtra currently has open capacity for liquid vial projects and can support rapid tech transfer.

Explore how INCOG BioPharma's purpose-built, state-of-the-art, 90,000 ft² facility designed for drug product fill/finish manufacturing can help support your biologic drug product through clinical trials and commercialization.

Cambrex recently expanded its API development and small-scale commercial capabilities in High Point, NC. We discuss how this facility and the Cambrex network are evolving to enhance capabilities and accelerate API development.

Explore an overview of Adare’s integrated end-to-end oral dose capabilities, with a focus on high potency capacity and the recently expanded packaging and serialization capabilities at our Philadelphia facilities.

Review Pfizer CentreOne’s overall small molecule capabilities. From pellets, tablets, and capsules to innovative release profiles, Pfizer CentreOne has the global expertise to help meet your needs across a wide range of platforms and technologies.

Our core capabilities include bioavailability enhancement, respiratory delivery, and multiparticulates. Our early-phase clinical facility provides agile, quick-to-clinic capabilities, and our experts in our commercial facility will ensure the success of your molecule.

We are a leading CRDMO committed to delivering innovative solutions. Our state-of-the-art facilities, advanced technology platforms, and strict quality control systems enable us to provide reliable, cost-effective, and efficient services to our clients.

Uncover Nanoform's CESS technology for nanoparticle generation and the types of particles that can be generated without the need for solvents or excipients. Review our manufacturing capabilities as well as potential production volumes.

Discover our increased available capacity for the manufacture and packaging of highly potent drug products, including solid oral and liquid dosage forms. These investments build on 35+ years of experience in the handling of potent drug products.

Major hurdles for the manufacture of AAV vectors include scalability, production yields, quality, and a clean feed-stream. We have developed a high-yielding, scalable suspension platform for the production of high-quality AAV.

FUJIFILM Diosynth Biotechnologies' viral gene therapy capacity and capabilities include exosomes, gene therapies, oncolytic viruses, and vaccines. Explore how FDB is poised to facilitate the development and manufacture of your novel advanced therapeutic.

We bring together R&D platforms, cGMP manufacturing, and new technologies. BaseCamp supports partnerships across R&D, process and analytical development, cell and vector manufacturing processes, regulatory, manufacturing, and automation.